Determination of HER-2/Neu Overexpression and Clinical Predictors of Survival in a Cohort of 347 Patients with Primary Malignant Brain Tumors

References

• Hung M. C., Lau Y. K. Basic science of HER-2/neu: a review. Semin. Oncol. 1999; 26(Suppl 12)51–59, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Schneider P. M., Hung M. C., Chiocca S. M., Manning J., Zhao X. Y., Fang K., Roth J. A. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res. 1989; 49(18)4968–4971, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Weiner D. B., Nordberg J., Robinson R., Nowell P. C., Gazdar A., Greene M. I., Williams W. V., Cohen J. A., Kern J. A. Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res. 1990; 50(2)421–425, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Zhang X., Silva E., Greshenson D., Hung M. C. Amplification and rearrangement of c-erbB proto-oncogenes in cancer of human female genital tract. Oncogene 1989; 4: 985–989, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Yokota J., Yamamoto T., Miyajima N., Toyoshima K., Nomura N., Sakamoto H., Yoshida T., Terada M., Sugimura T. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 1989; 2: 283–287, [CSA]
   Web of Science ®Google Scholar
• Riben M. W., Malfetano J. H., Nazeer T., Muraca P. J., Ambros R. A., Ross J. S. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma. Mod. Path. 1997; 10: 823–831, [CSA]
   PubMed Web of Science ®Google Scholar
• Costa M. J., Walls J. Epidermal growth factor receptor and c-erbB-2 oncoprotein expression in female genital tract carcinomas (malignant mixed mullerian tumors) Clinicopathologic study of 82 cases. Cancer 1996; 77: 533–542, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Dugan M. C., Dergham S. T., Kueway R. HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. Pancreas 1997; 14: 229–236, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kapitanovic S., Radosevic S., Kapitanovic M., Andelinovic S., Ferencic Z., Tavassoli M., Primorac D., Sonicki Z., Spaventi S., Pavelic K., Spaventi R. The expression of p185 (HER-2/neu) correlates with stage of disease and survival in colorectal cancer. Gastroenterology 1997; 112: 1103–1113, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Costa M. J., Walls J., Trelford J. D. C-erbB-2 oncoprotein over-expression in uterine cervix carcinoma with glandular differentiation. A frequent event but not an independent prognostic marker because it occurs late in the disease. Am. J. Clin. Pathol. 1995; 104: 634–642, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mellemgaard A., Geisler C. H., Storm H. H. Risk of kidney cancer and other second solid malignancy in-patients with chronic lymphocytic leukemias. Eur. J. Haematol. 1994; 53: 218–222, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Gusterson B. A., Gelber R. D., Goldrisch A., Price K. N., Save-Soderborgh J., Anbazhagan R., Styles J., Rudenstam C. M., Golouh R., Reed R. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J. Clin. Oncol. 1992; 10: 1049–1056, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Berchuk A., Kamel A., Whitaker R. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Red. 1990; 50: 4087–4091
   PubMed Web of Science ®Google Scholar
• Potti A., Ganti A. K., Koch M., Mehdi S. A., Levitt R. Identification of HER-2/neu overexpression and the clinical course of lung carcinoma in non-smokers with chronic lymphocytic leukemia. Lung Cancer Nov., 2001; 34(2)227–232, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kristt D. A., Yarden Y. Differences between phosphotyrosine accumulation and neu/erbB-2 receptor expression in astrocytic proliferative processes: implications for glial oncogenesis. Cancer 1996; 78: 1272–1283, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Schlegel J., Stumm G., Brandle K., Merdes Brandle;A., Mechtersheimer G., Hynes N. E., Kiessling M. Amplification and differential expression of members of the erbB-gene family in human glioblastoma. J. Neurooncol. 1994; 22(3)201–207, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Schwechheimer K., Laufle R. M., Schmahl W., Knodlseder M., Fischer H., Hofler H. Expression of neu/c-erbB-2 in human brain tumors. Human Pathol. 1994; 25(8)772–780, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hwang S. L. Expression of epidermal growth factor receptors and c-erbB-2 proteins in human astrocytic tumors. Kaohsiung J. Med. Sci. 1997; 13(7)417–424, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Herms J. W., Behnke J., Bergmann M., Christen H. J., Kolb R., Wilkening M., Markakis E., Hanefeld F., Kretzschmar H. A. Potential prognostic value of c-erbB-2 expression in medulloblastomas in very young children. J. Pediatr. Hematol./Oncol. 1997; 19(6)510–515, [CROSSREF]
   Web of Science ®Google Scholar
• Gilbertson R. J., Jaros E. B., Perry R. H., Pearson A. D. Prognostic factors in medulloblastoma. Lancet 1992; 340: 8817, [CROSSREF]
   Google Scholar
• Gilbertson R. J., Pearson A. D., Perry R. H., Jaros E., Kelly P. J. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br. J. Cancer 1995; 71(3)473–477, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Chozick B. S. Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas. J. Neurooncol. 1996; 27(2)117–126, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Haapasalo H., Hyytinen E., Sallinen P., Helin H., Kallioniemi O. P., Isola J. c-erbB- 2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. Br. J. Cancer 1996; 73(5)620–623, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Nam D. H. The effect of isochrome 17q presence, proliferative and apoptotic indices, expression of c-erbB-2, bcl-2 and p53 proteins on the prognosis of medulloblastoma. J. Korean Med. Sci. 2000; 15(4)452–456, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Jimenez R. E., Wallis T., Tabasczka P., Visscher D. W. Determination of HER-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod. Path. 2000; 13: 37–45, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Bluehler H., Bangemann N., Evers K. Effective HER-2/neu diagnosis in breast cancer by a combination of immunohistochemistry and FISH. Proc. Am. Soc. Clin. Oncol. 2000; 19: 76a, Abstract
   Google Scholar
• Mass R. D., Sanders C., Charlene K. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials. Proc. Am. Soc. Clin. Oncol. 2000; 19: 75a, Abstract
   Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457–481, [CSA]
   Web of Science ®Google Scholar
• Nakamura M., Konishi N., Tsuzuki T. Analysis of prognostic and survival factors related to treatment of low-grade astrocytomas in adults. Oncology 2000; 58(2)108–116, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Gehan E. A., Walker M. D. Prognostic factors for patients with brain tumors. Natl. Cancer Inst. Monogr. 1977; 46: 189–195, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Salcman M., Scholtz H., Kaplan R. S., Kaplan R. S., Kulik S. Long-term survival in patients with malignant astrocytoma. Neurosurgery 1994; 34(2)213–219, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Takeuchi K., Hoshino K. Statistical analysis of factors affecting survival after glioblastoma multiforme. Acta Neurochir. 1977; 37(1–2)57–73
   PubMed Web of Science ®Google Scholar
• Hwang S. L., Hong Y. R., Chai C. Y. Prognostic evaluation in supratentorial astrocytic tumors using p53, epidermal growth factor receptor, c-erbB-2 immunostaining. Kaohsiung J. Med. Sci. 1998; 14(10)607–615, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Tuzi N. L., Venter D. J., Kumar S., Staddon S. L., Lemoine N. R., Gullick W. J. Expression of growth factor receptors in human brain tumors. Br. J. Cancer 1991; 63(2)227–233, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar